慢性淋巴细胞白血病中的Richter转化:德国CLL研究组一线治疗试验的汇总分析
该汇总分析纳入2975例晚期CLL患者,评估Richter转化(RT)的发生率、特征与结局。RT患者自CLL诊断起中位OS为71个月,无RT者为167个月(HR 2.64,CI 2.09-3.33);RT诊断后中位OS仅9个月。
要点
- 一线化疗或化学免疫治疗后RT发生率为3%,以弥漫大B细胞淋巴瘤为主。
- RT患者自CLL诊断起中位OS显著缩短(71 vs 167个月,HR 2.64)。
- RT诊断后中位OS仅9个月,预后极差。
核心结论
- 在大型GCLLSG试验队列中,3%的CLL患者在一线化疗或化学免疫治疗后发生Richter转化。
- 该数据集证实RT与持续的不良预后和高死亡率相关。
研究设计与样本
- 汇总分析德国CLL研究组(GCLLSG)一线治疗试验,共回顾2975例晚期CLL患者。
- 汇总临床、实验室和遗传学数据,采用Kaplan-Meier法分析从CLL诊断、一线治疗或RT诊断开始的时间事件数据。
主要发现
- 中位观察时间为53个月(四分位距38.1-69.5)。
- 无RT患者自初始CLL诊断起中位OS为167个月,RT患者为71个月(HR 2.64,CI 2.09-3.33)。
- RT诊断后中位OS为9个月。
临床怎么用
- CLL患者一线化疗或化学免疫治疗后应警惕RT发生,发生率为3%。
- RT患者预后极差,RT诊断后中位OS仅9个月,需积极评估和治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Richter transformation (RT) is defined as development of aggressive lymphoma in patients (pts) with CLL. The incidence rates of RT among pts with CLL range from 2 to 10%. The aim of this analysis is to report the frequency, characteristics and outcomes of pts with RT enrolled in trials of the GCLLSG. A total of 2975 pts with advanced CLL were reviewed for incidence of RT. Clinical, laboratory, and genetic data were pooled. Time-to-event data, starting from time of CLL diagnosis, of first-line therapy or of RT diagnosis, were analyzed by Kaplan-Meier methodology. One hundred and three pts developed RT (3%): 95 pts diffuse large B-cell lymphoma (92%) and eight pts Hodgkin lymphoma (8%). Median observation time was 53 months (interquartile range 38.1-69.5). Median OS from initial CLL diagnosis for pts without RT was 167 months vs 71 months for pts with RT (HR 2.64, CI 2.09-3.33). Median OS after diagnosis of RT was 9 months. Forty-seven pts (46%) received CHOP-like regimens for RT treatment. Three pts subsequently underwent allogeneic and two pts autologous stem cell transplantation. Our findings show that within a large cohort of GCLLSG trial participants, 3% of the pts developed RT after receiving first-line chemo- or chemoimmunotherapy. This dataset confirms the ongoing poor prognosis and high mortality associated with RT.
引用
- Al-Sawaf O, Robrecht S, Bahlo J, et al. Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials. Leukemia. 2020. PMID: 32203141. doi:10.1038/s41375-020-0797-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。